Not a good buy right now for an impatient buyer: despite being extremely oversold, momentum is still bearish (MACD histogram negative and worsening) and there’s no near-term catalyst in the news.
Price is hovering just above key support (S1 2.553) in pre-market (2.60); this can produce a bounce, but the setup is more of a tactical rebound attempt than a clean trend entry.
Options flow is mixed-to-bearish on the day (puts dominating volume), and the company’s latest quarter showed revenue growth but sharp profit/EPS deterioration, limiting confidence in a sustained rally.
Trend/Momentum: Bearish momentum remains in control; MACD histogram is -0.0309 and negatively expanding (downtrend pressure still increasing).
RSI: RSI(6) at 13.25 = deeply oversold, which often precedes short-term bounces, but oversold alone is not a reversal signal.
Moving Averages: Converging MAs suggests the stock may be trying to stabilize, but there’s no confirmed turn yet.
Key levels: Pivot 2.789 (overhead), Resistance 3.025 / 3.171; Support 2.553 (S1) then 2.407 (S2). Pre-market 2.60 is only slightly above S1—loss of S1 would likely invite a move toward S2.
Pattern-based odds (provided): ~60% chance of a small next-day move (+0.65%); stronger week estimate (+7.3%) suggests bounce potential, but this conflicts with current bearish momentum signals.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI ratio 0.48 (calls > puts) leans bullish on longer-held positioning.
Today’s sentiment (Volume): Put/Call volume ratio 4.0 (puts dominating today’s tape), which is bearish near-term.
Activity level: Total volume 25 but ~22.32x the 30-day average; open interest today 8,481 and ~106% vs avg—attention is elevated, though absolute volume is still small.
Volatility: 30D IV ~100% vs HV ~71% (options pricing in large moves). IV percentile 44.8 / IV rank 18.47 = elevated but not extreme versus its own history.
Technical Summary
Sell
10
Buy
3
Positive Catalysts
~
near support (S1 ~2.
can fuel a fast mean-reversion bounce.
supports the business demand narrative.
Neutral/Negative Catalysts
Bearish momentum is still worsening (MACD histogram negative and expanding), increasing risk of support breakdown.
Profitability deterioration: 2025/Q3 net income and EPS fell sharply YoY, which can cap rallies.
Mixed Wall Street view: Roth keeps Neutral and cited “flattening” revenue/EBITDA outlook—directly contradicts a strong bull case.
Options tape today skewed bearish (put-heavy volume), suggesting traders are leaning defensive in the very near term.
No identifiable event-driven catalyst from recent news to force a re-rating immediately.
Net Income: $1.695M, down -354.12% YoY (major deterioration).
EPS: $0.04, down -200% YoY (earnings power weakening).
Gross Margin: 34.83%, +0.58 YoY (slight improvement, but not enough to offset earnings decline).
Takeaway: growth exists, but the quality of earnings trend is negative, which reduces conviction for buying into weakness without a clear reversal signal.
2025-11-06: Roth Capital kept Neutral, raised PT to $3.25 from $2.25 after Q3, citing cost controls but also “flattening” revenue/EBITDA outlook.
Wall Street pros: potential upside implied by initiation; cost controls may support near-term EBITDA.
Wall Street cons: neutrality from Roth + commentary about flattening outlook; implies upside may be limited unless growth re-accelerates.
Wall Street analysts forecast CCLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCLD is 6.42 USD with a low forecast of 3.25 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CCLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCLD is 6.42 USD with a low forecast of 3.25 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.250
Low
3.25
Averages
6.42
High
8
Current: 2.250
Low
3.25
Averages
6.42
High
8
ThinkEquity
NULL -> Buy
initiated
$8
AI Analysis
2025-11-24
Reason
ThinkEquity
Price Target
$8
AI Analysis
2025-11-24
initiated
NULL -> Buy
Reason
ThinkEquity initiated coverage of CareCloud with a Buy rating and $8 price target.
Roth Capital
Richard Baldry
Neutral
upgrade
2025-11-06
Reason
Roth Capital
Richard Baldry
Price Target
2025-11-06
upgrade
Neutral
Reason
Roth Capital analyst Richard Baldry raised the firm's price target on CareCloud to $3.25 from $2.25 and keeps a Neutral rating on the shares. The firm upped estimates post the Q3 report. Cost controls and cuts will extend CareCloud's adjusted EBITDA in the near-term, the analyst tells investors in a research note. Roth cites the company's "flattening" revenue and EBITDA outlook for its hold rating.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CCLD
